Toshiba at EuroCIS: Empowering Retailers to “Create Your Tomorrow”
At EuroCIS 2025, Toshiba Global Commerce Solutions showcases how it empowers retailers with its innovative solutions portfolio for smart stores, customer personalization, and security (booth in hall 9 #B42). The international trade fair will take place on February 18-20 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213535650/en/
The new TCx 820 all-in-one POS system is suitable for all types of store environments as it is available in various formats and screen sizes. (Photo: Business Wire)
“In a world brimming with possibilities, every retailer can shape their own future and deliver exceptional customer experiences and growth with the help of an experienced partner,” says Robin Lyon, Executive Director of Channels & Marketing, Toshiba Global Commerce Solutions. “To empower retailers to create their own tomorrow, Toshiba delivers complete solutions comprising of its modular MxP® hardware, software and services harnessing the power of AI, computer vision, and other transformative technologies. Advanced self-service solutions and new POS technologies are designed to meet the unique needs of retailers, no matter their size or segment.”
Innovative Solutions shown on the Toshiba booth
- Loss prevention and customer experience at self-checkout: The new Modular eXpansion Platform (MxP®) provides self-checkout solutions in a sleek design tailored for all retail segments. Various form factors feature capabilities for loss prevention and produce recognition using AI, computer vision and IoT sensors to recognize shrinkage and speed up transactions. Toshiba’s TCx® EDGEcam+ cameras monitor customer behaviors without in-store servers, enhancing security throughout the checkout area. For fast scan-free self-checkout, the MxP® VisionKiosk uses computer vision and AI to automatically identify items for a seamless shopping experience.
- Flexible POS-systems and versatile Touch Displays: The new TCx® 820 all-in-one POS-system and TCx® Touch Displays are available in multiple formats with a sleek design ready for all retail segments. They are configurable in five formats enabling seamless integration into any retail environment or use case. Screen sizes range from 10” to 24” with both landscape and portrait orientations available.
- Personalized shopping experiences: Catch Retail is an AI retail media platform for physical spaces, monetizing first-party data for retailers and brands, enabling them to reach new, targeted audiences in stores. Catch will demonstrate how they are revolutionizing in-store customer engagement, brand loyalty and revenue growth by enabling personalized media through various shopping touchpoints.
- AI-powered refrigeration management: Axiom Cloud will demonstrate how retailers can reduce energy consumption and save on maintenance costs in their cold chain operations using AI.
- Toshiba Commerce Marketplace: Aimed at meeting the ever-evolving needs of retail, the Toshiba Commerce Marketplace enables retailers to connect to an extensive network of industry-leading technology partners and solutions to stay competitive in an increasingly digital world, to enhancebusiness operations, and improve the shopping experience. Today, the Commerce Marketplace includes partners such as Adyen, Zebra, Datalogic, Ingenico, Ecrebo, Qualcomm, Honeywell, and Aptos, amongst others.
Toshiba will speak on the Blue and Red Stages
Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:
February 18 at 11:40 - 12:00 on the Blue Stage (hall 10 G65)
The Business Benefits of Switching to a Secure Retail Cloud
Johnny Flynn, Retail Cloud Architect, Toshiba Global Commerce Solutions
February 19 at 14:00 - 14:20 on the Red Stage (hall 10 G01)
From Simple Break-Fix Maintenance to Sustainable Business Availability Management
Catherine Bataille, Director Professional Services, Toshiba Global Commerce Solutions
Dries de Beul, Technical Design & Solution Architect, Toshiba Global Commerce Solutions
To arrange to meet with Toshiba at EuroCIS, follow this link: Book a Meeting with Toshiba
About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs.
Visit commerce.toshiba.com and engage with us on:
LinkedIn - YouTube - Facebook - Instagram: @toshibacommerce
X/Twitter: @ToshibaCommerce
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213535650/en/
Contacts
MEDIA CONTACT:
Toshiba Global Commerce Solutions
Robin Lyon
robin.lyon@toshibagcs.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom